embalaje : 100mg
Teléfono : +1 850 650 7790
Synonyms: Pefabloc SC, AEBSF HCl
| Description | AEBSF hydrochloride (Pefabloc SC) is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, thrombin, plasmin, and trypsin. |
| In vitro | In a mouse model of cockroach allergen-induced asthma, AEBSF was able to mitigate respiratory reactions and potential inflammation. Intraperitoneal injection of 76.8 mg/kg AEBSF daily in mice lethally inoculated with Toxoplasma gondii extended their survival period. |
| In vivo | AEBSF is a serine protease inhibitor that suppresses the lysis of leukemia cells by macrophages without inhibiting the secretion of TNF-α and IL-1β by these cells. In five different human cell lines, AEBSF inhibits the formation of amyloid-beta (Aβ) by blocking the secretion of both neural and non-neural β-secretase products. Additionally, AEBSF disrupts embryonic growth within the endometrium and modifies protein secretion mechanisms to prevent the adhesion of HeLa cells in human umbilical vein endothelial cells. |
| Synonyms | Pefabloc SC, AEBSF HCl |
| Cell Research | The HeLa cells suspended in RPMI-1640 media containing 10% FCS are plated into each well of a 96-well microplate (5×103 cells/200 μL/well). After incubation for 24 h at 37°C, cells are treated with different doses of AEBSF (0, 25, 50, 100 μg/mL) for 48 h. Then, 20 μL fresh 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-diphenytetrazoliumromide (MTT) reagent (5 μg/μL) is added into each well, and cells are cultured at 37°C in 5% CO2 for another 4 h. The media are discarded carefully, and 150 μL DMSO is added. Absorbance is read on a microplate reader at dual wavelengths of 540 and 620 nm. |
| Molecular Weight | 239.69 |
| Formula | C8H11ClFNO2S |
| Cas No. | 30827-99-7 |
| Smiles | Cl.NCCc1ccc(cc1)S(F)(=O)=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 24 mg/mL (100.13 mM), Sonication is recommended. DMSO: 247 mg/mL (1030.5 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (20.86 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
